Diabetics who rely on glucose monitors are alarmed by recall linked to 7 deaths

Glucose Monitor Recall Sparks Concern Among Diabetics Over 7 Fatal Cases

Abbott, a leading medical equipment manufacturer, recently issued a recall for approximately 3 million FreeStyle Libre 3 and Libre 3 Plus glucose sensors, citing their potential to generate misleading low blood sugar alerts. The company reported seven deaths and over 730 serious injuries globally linked to the issue, leaving many diabetes patients anxious about the reliability of their devices. One such case involves Michael Ford, a 68-year-old man with Type 2 diabetes, whose life was tragically affected by the faulty technology.

Michael Ford’s son, Davonte, was his primary caregiver, managing his daily routine and responding to fluctuations in his blood sugar. On a November morning in Oakland, California, Davonte was alerted by Michael’s FreeStyle Libre 3 Plus sensor to a low reading. Without hesitation, he administered fast-acting carbohydrates as advised by medical professionals. However, this action came too late. The sensor’s reading was incorrect, and Michael’s blood sugar levels continued to drop, eventually reaching a critical point.

“My heart just dropped. Obviously, there’s a problem here.”

By the time Davonte realized the severity, Michael’s blood sugar had surged to 551 mg/dL—a level more than three times the normal range. The family’s attempt to stabilize his condition failed, and Michael passed away in a hospital intensive care unit after multiple cardiac arrests. A lawsuit filed by Davonte, 25, claims the sensor’s “catastrophically inaccurate” reading was the direct cause of his death, though Abbott’s recall list did not include the specific serial number from his device.

Diabetes, a chronic condition affecting around 40.1 million Americans, demands consistent monitoring to prevent complications like blindness or organ damage. The Abbott recall has intensified scrutiny over the growing dependence on glucose monitoring technology, highlighting both its benefits and the risks when malfunctions occur. In addition to Davonte’s wrongful death suit, three class-action lawsuits have been proposed in the U.S., with other plaintiffs in California, Washington, and North Carolina planning to join the legal action.

Patients and attorneys are questioning whether the recall adequately addressed all affected sensors. Abbott cited 860 injuries in its latest update, but concerns remain about the true extent of the issue. The company’s spokesperson, Lindsy Delco, emphasized that not every sensor in the recalled lots was faulty and that adverse events may stem from various causes. She noted that the production line problem was swiftly resolved, though the company has yet to respond to Davonte’s lawsuit.

Company Response and Medical Perspective

Delco expressed sorrow over Michael’s death, stating Abbott takes all reports seriously. The company also assured that individuals experiencing issues should reach out to customer service. Meanwhile, Dr. Amy Warriner, an endocrinologist, highlighted the transformative role of continuous glucose monitors in diabetes care. “Over 20 years ago, the introduction of these devices revolutionized how patients track their blood sugar,” she said, noting their convenience compared to traditional finger sticks.

Leave a Reply

Your email address will not be published. Required fields are marked *